Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMandarin In.sg Regulatory News (MDO)

  • This share is currently suspended. It was suspended at a price of 1.65
  • There is currently no data for MDO

Company Board Changes

16 Jul 2024 10:49

RNS Number : 6025W
Mandarin Oriental International Ltd
16 July 2024
 

MANDARIN ORIENTAL INTERNATIONAL LIMITED

 

COMPANY BOARD CHANGES

 

 

Mandarin Oriental International Limited (the 'Company') is pleased to announce the following changes to the Board:

 

Fabrice Megarbane will join the Board of the Company as an Independent Non-Executive Director with effect from 1 August 2024.

 

John Witt, Group Managing Director of Jardine Matheson, will step down as a Director from the Company's Board and as a member of the Remuneration and Nominations Committees. Adam Keswick will step down from the Nominations Committee and Graham Baker will step down from the Remuneration Committee. Adam remains as a Director. These changes will all take effect from 22 July 2024.

 

The Company is also announcing that Sean Ward will be appointed as Company Secretary, with effect from 22 July 2024, succeeding Jonathan Lloyd.

 

Fabrice Megarbane is the Chief Global Growth Officer of L'Oréal. He was previously President and CEO of L'Oréal North Asia and CEO of L'Oréal China and serves on its global executive committee. He managed a combined revenue of more than EUR10 billion, which accounts for over 25 percent of L'Oréal's global business, and an organisation of 20,000 people. Fabrice started his marketing career at L'Oréal S.A. in 2000. He brings multi-market experience, combining emerging and developed markets, including Europe, the Middle East, Africa, Germany, China and now North Asia.

 

Commenting on these changes, Chair Ben Keswick said: "I am pleased to welcome Fabrice to our Board, which will benefit from his extensive experience at L'Oréal. He is an accomplished and passionate marketer and brand builder with a deep consumer focus and extensive experience in digital transformation.

 

We will continue to enhance the composition of our Board, bringing in relevant expertise to help our management team deliver on their strategy and build long-term shareholder value.

 

I would also like to thank John and Jonathan for their service to the Board."

 

 

Jonathan Lloyd, Jardine Matheson LimitedFor and on behalf of Mandarin Oriental International Limited

 

16th July 2024

 

www.mandarinoriental.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAGPUBCMUPCUBQ
Date   Source Headline
19th Jan 20261:45 pmRNSCompletion of Acquisition by Jardine Strategic
16th Jan 20267:00 amRNSCourt Sanction of Scheme of Arrangement
9th Jan 20269:19 amRNSOCB Dividend
31st Dec 20257:22 amRNSUpdate on OCB Sale and Acquisition Timeline
31st Dec 20257:22 amRNSUpdate on OCB Sale and Acquisition Timeline
8th Dec 20253:47 pmRNSResults of Court Meeting & Special General Meeting
21st Nov 20259:58 amRNSInterim Management Statement
14th Nov 202511:37 amRNSReplacement: Publication of Shareholder Circular
14th Nov 20259:38 amRNSAnnouncement (Publication of Shareholder Circular)
17th Oct 202510:24 amRNSRecommended Cash Acquisition of Mandarin Oriental
17th Oct 202510:21 amRNSSale of 301,555 sq.ft. of One Causeway Bay
2nd Oct 202510:20 amRNSDividend Declaration
30th Sep 20257:00 amRNSRESPONSE TO MEDIA SPECULATION
25th Sep 202510:23 amRNSBlock listing Interim Review
28th Jul 202512:33 pmRNSHalf-year Results
11th Jul 202510:28 amRNSNotification to Untraced Shareholders
15th May 202511:44 amRNSINTERIM MANAGEMENT STATEMENT
2nd May 20251:02 pmRNSResult of AGM
30th Apr 202510:24 amRNSDividend Declaration
7th Apr 202510:39 amRNSAnnual Financial Report
25th Mar 20259:20 amRNSBlock listing Interim Review
5th Mar 20251:42 pmRNS2024 PRELIMINARY RESULTS
14th Nov 20249:43 amRNSINTERIM MANAGEMENT STATEMENT
4th Nov 20249:22 amRNSDirectorate Change
2nd Oct 202410:26 amRNSDividend Declaration
25th Sep 202410:19 amRNSBlock listing Interim Review
31st Jul 202410:17 amRNSCompany Board Change
24th Jul 20243:06 pmRNSHalf-year Report
16th Jul 202410:49 amRNSCompany Board Changes
12th Jun 202411:59 amRNSDisposal
23rd May 202410:44 amRNSINTERIM MANAGEMENT STATEMENT
8th May 202412:38 pmRNSResult of AGM
2nd May 202410:23 amRNSDividend Declaration
9th Apr 202410:28 amRNSAnnual Financial Report
25th Mar 20249:26 amRNSBLOCK LISTING INTERIM REVIEW
7th Mar 202410:04 amRNS2023 Preliminary Results
1st Mar 20249:25 amRNSCHANGE OF SINGAPORE BRANCH REGISTRAR
22nd Dec 20231:18 pmRNSMO Signs Option to sell MO, Paris
24th Nov 20239:22 amRNSDirectorate Change
9th Nov 20239:54 amRNSINTERIM MANAGEMENT STATEMENT
27th Sep 202310:28 amRNSDividend Declaration
25th Sep 202310:33 amRNSBlock listing Interim Review
1st Sep 202310:27 amRNSDirector Declaration
28th Jul 202310:33 amRNSHalf-year Results
18th May 202310:23 amRNSInterim Management Statement
4th May 202312:31 pmRNSResult of AGM
2nd May 202310:17 amRNSDirectorate Change
3rd Apr 202310:26 amRNSAnnual Financial Report
31st Mar 202310:24 amRNSTotal Voting Rights
27th Mar 202310:30 amRNSBlock listing Interim Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.